Biopharma company Biological E (BE) has forged a strategic partnership with Bavarian Nordic to manufacture the Chikungunya (CHIKV) vaccine, VIMKUNYA CHIKV VLP. The collaboration aims to increase access to the vaccine in low- and middle-income countries.
Technology Transfer and Job Creation
The agreement involves an initial technology transfer, followed by commercial manufacturing. This initiative has the potential to create up to 300 new jobs. BE announced the partnership at BioAsia 2025. By expanding production, the companies intend to enhance vaccine availability in underserved regions.
About VIMKUNYA CHIKV VLP
VIMKUNYA is an adjuvanted VLP recombinant protein vaccine. It actively immunizes individuals aged 12 and older against the chikungunya virus. VLPs (virus-like particles) do not contain genetic material, they cannot infect cells, reproduce, or cause disease. The vaccine induces immunity by generating neutralizing antibodies against specific CHIKV proteins, which helps in neutralizing the live virus. An added adjuvant enhances the immune response, making the vaccine more effective.
Expanding Manufacturing and Regulatory Approvals
BE will first implement the drug product manufacturing process and may later incorporate drug substance production. The companies have also agreed to expand capacity to ensure a steady supply of the vaccine to endemic regions. After the technology transfer, BE will apply for regulatory approvals and commence commercial production at its existing facilities in Genome Valley, Hyderabad. These facilities will be further upgraded to accommodate vaccine manufacturing.
Bavarian Nordic’s Global Expansion Strategy
Bavarian Nordic continues to seek opportunities to extend the global reach of its Chikungunya vaccine. The company is actively working with partners to distribute the vaccine beyond the U.S. and Europe. Recently, the vaccine received its first approval in the U.S. for individuals aged 12 and older. Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, paving the way for broader regulatory approvals.
Leaders Express Confidence in the Partnership
Mahima Datla, Managing Director of Biological E Ltd emphasized, “Our large-scale manufacturing capabilities and track record in global vaccine access align perfectly with Bavarian Nordic’s vision. We are committed to using advanced manufacturing technologies. Our goal is to tackle health challenges in endemic regions. This collaboration will significantly contribute to Chikungunya prevention worldwide”.
Paul Chaplin, President and CEO of Bavarian Nordic highlighted, “Our partnership with BE marks a significant step in ensuring broader access to the Chikungunya vaccine. Expanding production capacity is essential to meet the growing demand for solutions to prevent Chikungunya in vulnerable populations”.
Conclusion
The partnership between Biological E and Bavarian Nordic marks a crucial step in global Chikungunya prevention efforts. As reported by msn.com, by leveraging advanced manufacturing capabilities and expanding vaccine access, this collaboration has the potential to protect millions from the debilitating effects of the disease.
